Heterocyclic GABAA Receptor Modulators: Emerging Therapeutic Strategies for Epilepsy Management

Epilepsy remains a complex neurological disorder with a significant proportion of patients exhibiting drug-resistant epilepsy, underscoring the need for novel therapeutic solutions. Despite the availability of numerous antiepileptic drugs, the γ-aminobutyric acid (GABA) system, particularly the GABA_A receptor, remains one of the most validated targets for anticonvulsant drug design due to its central role in inhibitory neurotransmission. This review provides a comprehensive analysis of next-generation GABA_A receptor modulators, exploring their pharmacological mechanisms, receptor subtype selectivity, and structure-activity relationships. Various heterocyclic scaffolds, including benzodiazepines, imidazoles, thiazoles, oxadiazoles, and bicyclic or fused ring systems, exhibit promising anticonvulsant properties with selective receptor binding and reduced side effects. A systematic literature search was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines using PubMed, Scopus, and Web of Science databases from 2018 to 2024. Recent advancements in molecular design, docking studies, and in vivo evaluations highlight how specific molecular modifications enhance receptor affinity, blood-brain barrier permeability, and metabolic stability. Key findings highlight the structural features that enhance receptor affinity, pharmacokinetics, and efficacy. Future research must concentrate on designing these heterocyclic frameworks more efficiently while evaluating their selective receptor binding and performing clinical research to develop advanced anticonvulsant medicines.